A high Breast Cancer Index (BCI) score means your tumor’s gene activity places you in a group with a significantly greater risk of the cancer returning in distant parts of the body, particularly in the years after you finish a standard five-year course of hormone therapy. In the largest validation studies, patients with high-risk BCI results had distant recurrence rates between 17% and 22% over 10 to 15 years, compared with roughly 2% to 7% for those in the low-risk group. Perhaps more importantly, a high score identifies you as someone likely to benefit from extending hormone therapy beyond five years.
What the BCI Test Actually Measures
The Breast Cancer Index is a gene expression test run on a sample of your original tumor tissue. It combines two separate biological signals into a single result. The first component evaluates how actively the tumor cells were dividing, which is a core indicator of aggressiveness. The second measures the ratio of two specific genes (often written as H/I) that reflect how the tumor responds to estrogen signaling. Together, these two components capture both the growth speed of the cancer and how strongly it’s driven by hormones.
The combined result sorts patients into low, intermediate, or high risk categories for distant recurrence. The test is designed for people with hormone receptor-positive, HER2-negative early-stage breast cancer, including those with up to three positive lymph nodes. Both premenopausal and postmenopausal patients are eligible, typically after completing four to five years of hormone therapy. That timing matters because the test’s core purpose is answering one question: should you keep taking hormone therapy beyond the standard five years?
How Risk Categories Break Down
BCI doesn’t return a single number on a simple 0-to-100 scale the way some other tests do. Instead, it classifies your result into risk groups using preset genetic cutoffs for each of its two components. You’re placed in the high-risk group when both the growth signal and the estrogen-response signal are elevated. If only one is elevated, the result falls into the intermediate range. When both are low, you’re in the low-risk group.
In the TransATAC study, which prospectively validated the test in over a thousand patients, the 10-year distant recurrence rates broke down clearly by group: 6.8% for low risk, 17.3% for intermediate risk, and 22.2% for high risk. A separate study focused on patients with one to three positive lymph nodes found an even starker gap. Among those who stayed cancer-free for at least five years, the risk of a late distant recurrence (between years 5 and 15) was just 1.3% in the low-risk group versus 16.1% in the high-risk group.
Why Late Recurrence Matters
Hormone receptor-positive breast cancers behave differently from other types. They can recur many years after initial treatment, sometimes a decade or more later. This makes predicting late recurrence (after year five) uniquely important, and it’s where BCI stands apart from other genomic tests.
In head-to-head comparisons from the TransATAC trial, BCI was the only test that significantly predicted late distant recurrence when adjusted for other risk factors. The 21-gene recurrence score (Oncotype DX) and the IHC4 panel both lost their predictive power for recurrences happening after year five, while BCI remained statistically significant. This is a critical distinction: many genomic tests can tell you about your risk in the first five years, but BCI is specifically validated to look further out.
What a High Score Means for Treatment
This is where a high BCI result becomes actionable. Standard hormone therapy for early-stage hormone receptor-positive breast cancer lasts five years. Extending it to 10 years can reduce recurrence, but it also means years of side effects like joint pain, hot flashes, bone thinning, and fatigue. The question is whether the benefit outweighs that burden for you specifically.
Clinical trial data shows the answer depends heavily on your BCI result. In patients with a high H/I ratio, extending treatment with an aromatase inhibitor cut the risk of recurrence by more than half. Patients with a low H/I ratio saw no meaningful benefit from the extra years of therapy. The BCI test identified roughly 50% of patients who appeared clinically high-risk but would not actually benefit from extended treatment, and conversely, patients who looked low-risk by standard measures but would gain significant benefit.
In practical terms: a high BCI score is a strong signal that completing a full 10 years of hormone therapy is worthwhile for you. A low score suggests you can likely stop at five years without meaningfully increasing your risk, sparing yourself the side effects of continued treatment.
Where BCI Fits in Clinical Practice
The BCI test was incorporated into NCCN guidelines in January 2021 and ASCO clinical practice guidelines in April 2022, which led to a significant increase in how often it’s ordered. It’s used for both premenopausal and postmenopausal patients with hormone receptor-positive, HER2-negative breast cancer who have zero to three positive lymph nodes. Patients with more than three positive nodes generally fall outside the validated population for the test.
The optimal time to take the test is around year four or five of hormone therapy, when you and your oncologist are deciding whether to continue treatment. The test is run on your stored tumor tissue from your original surgery or biopsy, so no new procedure is needed. Coverage by Medicare and private insurers has expanded since the guideline updates, though checking with your plan beforehand is still reasonable.
How BCI Compares to Other Genomic Tests
If you’ve already had an Oncotype DX or MammaPrint test, you might wonder whether BCI duplicates that information. It doesn’t. Those tests were primarily designed to guide chemotherapy decisions at the time of diagnosis and are strongest at predicting recurrence in the first five years. BCI serves a different purpose at a different point in your treatment timeline. It’s specifically built to predict what happens after year five and whether extending hormone therapy will help.
Some patients will have results from both an earlier genomic test and a later BCI test. These aren’t contradictory. They answer different questions at different stages of your care. A low Oncotype score at diagnosis might have helped you skip chemotherapy, while a high BCI score years later could mean extending your hormone therapy is the right move.